The global cholera vaccines market has been witnessing significant growth in recent years. Cholera is an infectious disease caused by ingestion of food or water contaminated with the bacterium Vibrio cholerae. The disease causes severe diarrhea and dehydration and can lead to death if left untreated. According to the World Health Organization (WHO), cholera affects 1.3 to 4 million people worldwide every year, resulting in 21,000 to 143,000 deaths. The increasing disease prevalence globally is anticipated to drive the demand for cholera vaccines over the forecast period.
Cholera vaccines help in preventing the disease through active immunization. They play a critical role in controlling and preventing cholera outbreaks and aid global efforts towards eliminating the disease.
Key Takeaways
Key players operating in the global cholera vaccines market include Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD. Sanofi's oral cholera vaccine, Dukoral, dominates the market.
Key Opportunities
Increasing focus on immunization programs in developing regions provides significant opportunities for Cholera Vaccines Market Demand manufacturers. The urgent need to strengthen cholera control and prevention globally through partnerships is likely to boost market growth.
Global Expansion
Key players are focusing on expanding their presence in high prevalence regions through partnerships and collaborations. Growing R&D investments to develop new generation oral cholera vaccines will further aid global market expansion over the coming years.
Market Drivers
Increasing disease prevalence worldwide due to lack of clean drinking water and proper sanitation is a major market driver. According to WHO data, 2.9 billion people are at risk of contracting cholera globally. Continued water and sanitation interventions are crucial to reducing the global disease burden.
Market Restraints
High costs associated with cholera vaccination, storage, and delivery challenges in remote regions act as key market restraints. Concerns regarding the effectiveness and duration of protection offered by some oral cholera vaccines also limit their widespread adoption.
Segment Analysis
The global cholera vaccines market is dominated by the oral segment which accounts for over 70% of the market share. The oral segment leads due to ease of administration and inducing immunity at mucosal surfaces which provides first line of defense against cholera infection. Other segments include inactivated vaccines and live attenuated vaccines. Within the oral vaccines category, Dukoral vaccine by Valneva dominates due to factors such as being the first oral cholera vaccine prequalified by WHO for use in endemic regions, long lasting protective efficacy, and widespread brand recognition in disease affected areas.
Global Analysis
The Americas region currently dominates the global cholera vaccines market and is expected to maintain its lead during the forecast period. Factors accounting for its large share include rising awareness about prevention of cholera, increasing promotional activities by key players, and availability of advanced healthcare facilities. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period owing to increasing prevalence of cholera in densely populated regions of South Asia and Southeast Asia coupled with rising immunization programs initiated by governments and non-profit organizations. As per WHO data, most cases of cholera originate from Asia, with India alone accounting for nearly 50% of global reported cases.
Get more insights on Cholera Vaccines Market
Comments
0 comment